Citation Impact
Citing Papers
Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis
2009
Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells
2012
Copper-free click chemistry in living animals
2010 StandoutNobel
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists
2024 StandoutScienceNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Pathways mediating VEGF-independent tumor angiogenesis
2009
EGFR Antagonists in Cancer Treatment
2008 Standout
Pericytes are required for blood–brain barrier integrity during embryogenesis
2010 StandoutNature
Combined modality therapy with TRAIL or agonistic death receptor antibodies
2011
A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
2017 Nature
Angiogenesis: A Team Effort Coordinated by Notch
2009
Necroptosis and its role in inflammation
2015 StandoutNature
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
2009 Standout
Axon Guidance Molecules in Vascular Patterning
2010
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
2010
Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family
2011
The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death
2016
Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns
2009
The Tn Antigen—Structural Simplicity and Biological Complexity
2011
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
2015
Glycopeptide-preferring Polypeptide GalNAc Transferase 10 (ppGalNAc T10), Involved in Mucin-type O-Glycosylation, Has a Unique GalNAc-O-Ser/Thr-binding Site in Its Catalytic Domain Not Found in ppGalNAc T1 or T2
2009 StandoutNobel
The role of mucin-type O-glycans in eukaryotic development
2010
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
2009
Lung Cancer
2008 Standout
Neuropilin‐1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer
2007
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Emerging Paradigms for the Initiation of Mucin-type Protein O-Glycosylation by the Polypeptide GalNAc Transferase Family of Glycosyltransferases
2011
Targeted treatments in colorectal cancer: state of the art and future perspectives
2010
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2013
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
2018
Cancer stem cells revisited
2017 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading
2010
IFNs, ISGylation and cancer: Cui prodest?
2012
Colorectal cancer
2013 Standout
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
2014
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
2013
Pancreatic Adenocarcinoma
2014 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Colorectal cancer
2019 Standout
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
2009 Nature
Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
2013
Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation
2009 Standout
Wnt/β-Catenin Signaling and Disease
2012 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Revealing the human mucinome
2022 StandoutNobel
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
2008
Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies
2010
Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes
2009
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
2010 StandoutNature
Malignant Gliomas in Adults
2008 Standout
Angiogenesis in brain tumours
2007
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
2013
Molecular regulation of angiogenesis and lymphangiogenesis
2007 Standout
Death receptor signal transducers: nodes of coordination in immune signaling networks
2009
Sox18 induces development of the lymphatic vasculature in mice
2008 StandoutNature
Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells
2011
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
2013
Measuring and Modeling Apoptosis in Single Cells
2011
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
2008
Pericytes regulate the blood–brain barrier
2010 StandoutNature
The TRAIL apoptotic pathway in cancer onset, progression and therapy
2008
Lectin Domains of Polypeptide GalNAc Transferases Exhibit Glycopeptide Binding Specificity
2011 StandoutNobel
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
2009
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
2014
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Targeting endothelial and tumor cells with semaphorins
2007
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Tumor Angiogenesis
2008 Standout
Cell death in health and disease
2007
Activity-based probes: discovering new biology and new drug targets
2010
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
CHD7 cooperates with PBAF to control multipotent neural crest formation
2010 StandoutNature
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Pancreatic cancer–associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation
2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer
2013
Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos
2008
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases
2016
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
2016
Density Variant Glycan Microarray for Evaluating Cross-Linking of Mucin-like Glycoconjugates by Lectins
2012 StandoutNobel
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
2011
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
2010
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
2012 StandoutNobel
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
2010
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
2013
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013
cFLIP Regulates Skin Homeostasis and Protects against TNF-Induced Keratinocyte Apoptosis
2013
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
2015
Engineering Orthogonal Polypeptide GalNAc-Transferase and UDP-Sugar Pairs
2019 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Life and death by death receptors
2009
Cancer Genome Landscapes
2013 StandoutScience
Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation
2015 StandoutNobel
Visualization and targeting of LGR5+ human colon cancer stem cells
2017 Nature
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
2008
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
2014
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Chemical Glycoproteomics
2016 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Regulated Cell Death: Signaling and Mechanisms
2014
Works of Sharon Yee being referenced
Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma
2007
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
2011
TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
2012
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
2007
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
2008
Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
2007
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
2007
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
2015